These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 11498467)

  • 1. Mice expressing only the mutant APOE3Leiden gene show impaired VLDL secretion.
    Mensenkamp AR; Teusink B; Baller JF; Wolters H; Havinga R; van Dijk KW; Havekes LM; Kuipers F
    Arterioscler Thromb Vasc Biol; 2001 Aug; 21(8):1366-72. PubMed ID: 11498467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic lipid accumulation, altered very low density lipoprotein formation and apolipoprotein E deposition in apolipoprotein E3-Leiden transgenic mice.
    Mensenkamp AR; van Luyn MJ; van Goor H; Bloks V; Apostel F; Greeve J; Hofker MH; Jong MC; van Vlijmen BJ; Havekes LM; Kuipers F
    J Hepatol; 2000 Aug; 33(2):189-98. PubMed ID: 10952236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apolipoprotein E participates in the regulation of very low density lipoprotein-triglyceride secretion by the liver.
    Mensenkamp AR; Jong MC; van Goor H; van Luyn MJ; Bloks V; Havinga R; Voshol PJ; Hofker MH; van Dijk KW; Havekes LM; Kuipers F
    J Biol Chem; 1999 Dec; 274(50):35711-8. PubMed ID: 10585451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Markedly increased secretion of VLDL triglycerides induced by gene transfer of apolipoprotein E isoforms in apoE-deficient mice.
    Tsukamoto K; Maugeais C; Glick JM; Rader DJ
    J Lipid Res; 2000 Feb; 41(2):253-9. PubMed ID: 10681409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Patatin-Like Phospholipase Domain Containing Protein 7 Facilitates VLDL Secretion by Modulating ApoE Stability.
    Wang X; Guo M; Wang Q; Wang Q; Zuo S; Zhang X; Tong H; Chen J; Wang H; Chen X; Guo J; Su X; Liang H; Zhou H; Li JZ
    Hepatology; 2020 Nov; 72(5):1569-1585. PubMed ID: 32103509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression and accumulation of apolipoprotein E as a cause of hypertriglyceridemia.
    Huang Y; Liu XQ; Rall SC; Taylor JM; von Eckardstein A; Assmann G; Mahley RW
    J Biol Chem; 1998 Oct; 273(41):26388-93. PubMed ID: 9756870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Both lipolysis and hepatic uptake of VLDL are impaired in transgenic mice coexpressing human apolipoprotein E*3Leiden and human apolipoprotein C1.
    Jong MC; Dahlmans VE; van Gorp PJ; Breuer ML; Mol MJ; van der Zee A; Frants RR; Hofker MH; Havekes LM
    Arterioscler Thromb Vasc Biol; 1996 Aug; 16(8):934-40. PubMed ID: 8696956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Very Low Density Lipoprotein Assembly Is Required for cAMP-responsive Element-binding Protein H Processing and Hepatic Apolipoprotein A-IV Expression.
    Cheng D; Xu X; Simon T; Boudyguina E; Deng Z; VerHague M; Lee AH; Shelness GS; Weinberg RB; Parks JS
    J Biol Chem; 2016 Nov; 291(45):23793-23803. PubMed ID: 27655915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apolipoprotein E2 (Lys146-->Gln) causes hypertriglyceridemia due to an apolipoprotein E variant-specific inhibition of lipolysis of very low density lipoproteins-triglycerides.
    de Beer F; van Dijk KW; Jong MC; van Vark LC; van der Zee A; Hofker MH; Fallaux FJ; Hoeben RC; Smelt AH; Havekes LM
    Arterioscler Thromb Vasc Biol; 2000 Jul; 20(7):1800-6. PubMed ID: 10894820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The transport of triglycerides through the secretory pathway of hepatocytes is impaired in apolipoprotein E deficient mice.
    Mensenkamp AR; Van Luyn MJ; Havinga R; Teusink B; Waterman IJ; Mann CJ; Elzinga BM; Verkade HJ; Zammit VA; Havekes LM; Shoulders CC; Kuipers F
    J Hepatol; 2004 Apr; 40(4):599-606. PubMed ID: 15030975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential effects of apolipoprotein E isoforms on lipolysis of very low-density lipoprotein triglycerides.
    Hara M; Iso-O N; Satoh H; Noto H; Togo M; Ishibashi S; Kimura S; Kadowaki T; Hashimoto Y; Tsukamoto K
    Metabolism; 2006 Aug; 55(8):1129-34. PubMed ID: 16839851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secretion-capture role for apolipoprotein E in remnant lipoprotein metabolism involving cell surface heparan sulfate proteoglycans.
    Ji ZS; Fazio S; Lee YL; Mahley RW
    J Biol Chem; 1994 Jan; 269(4):2764-72. PubMed ID: 8300609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic apolipoprotein E expression promotes very low density lipoprotein-apolipoprotein B production in vivo in mice.
    Maugeais C; Tietge UJ; Tsukamoto K; Glick JM; Rader DJ
    J Lipid Res; 2000 Oct; 41(10):1673-9. PubMed ID: 11013310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute inhibition of hepatic beta-oxidation in APOE*3Leiden mice does not affect hepatic VLDL secretion or insulin sensitivity.
    Duivenvoorden I; Teusink B; Rensen PC; Kuipers F; Romijn JA; Havekes LM; Voshol PJ
    J Lipid Res; 2005 May; 46(5):988-93. PubMed ID: 15716584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal of hypercholesterolemia in apolipoprotein E2 and apolipoprotein E3-Leiden transgenic mice by adenovirus-mediated gene transfer of the VLDL receptor.
    van Dijk KW; van Vlijmen BJ; van der Zee A; van't Hof B; van der Boom H; Kobayashi K; Chan L; Havekes LM; Hofker MH
    Arterioscler Thromb Vasc Biol; 1998 Jan; 18(1):7-12. PubMed ID: 9445249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fenofibrate increases very low density lipoprotein triglyceride production despite reducing plasma triglyceride levels in APOE*3-Leiden.CETP mice.
    Bijland S; Pieterman EJ; Maas AC; van der Hoorn JW; van Erk MJ; van Klinken JB; Havekes LM; van Dijk KW; Princen HM; Rensen PC
    J Biol Chem; 2010 Aug; 285(33):25168-75. PubMed ID: 20501652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The amino-terminal 1-185 domain of apoE promotes the clearance of lipoprotein remnants in vivo. The carboxy-terminal domain is required for induction of hyperlipidemia in normal and apoE-deficient mice.
    Kypreos KE; Morani P; van Dijk KW; Havekes LM; Zannis VI
    Biochemistry; 2001 May; 40(20):6027-35. PubMed ID: 11352738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperlipidemia in APOE2 transgenic mice is ameliorated by a truncated apoE variant lacking the C-terminal domain.
    Gerritsen G; Kypreos KE; van der Zee A; Teusink B; Zannis VI; Havekes LM; van Dijk KW
    J Lipid Res; 2003 Feb; 44(2):408-14. PubMed ID: 12576523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic MDM2 Causes Metabolic Associated Fatty Liver Disease by Blocking Triglyceride-VLDL Secretion via ApoB Degradation.
    Lin H; Wang L; Liu Z; Long K; Kong M; Ye D; Chen X; Wang K; Wu KK; Fan M; Song E; Wang C; Hoo RL; Hui X; Hallenborg P; Piao H; Xu A; Cheng KK
    Adv Sci (Weinh); 2022 Jul; 9(20):e2200742. PubMed ID: 35524581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secretion and uptake of nascent hepatic very low density lipoprotein by perfused livers from fed and fasted rats.
    Wilcox HG; Heimberg M
    J Lipid Res; 1987 Apr; 28(4):351-60. PubMed ID: 3585170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.